The National Institute on Aging has awarded $6.7 million to Dr. Damian Young, an investigator at Texas Children's Duncan Neurological Research Institute and director of the Center for Drug Discovery at Baylor College of Medicine, along with his collaborators, to build faster ways of identifying candidate treatments for Alzheimer's disease and related dementias. The five-year project pairs synthetic chemistry with artificial intelligence and translational science, with the stated aim of running the most expansive screening effort to date for compounds that act on Alzheimer's biology.
Drug discovery for dementia has been slow in large part because the screening step is slow: sifting through vast chemical space to find molecules that are both safe and effective consumes years before a compound ever reaches a clinical trial. Young's group intends to compress that step by feeding biological insights from Alzheimer's research worldwide into a chemistry and machine learning platform, letting the computational side narrow the field before the bench work begins.
There is a reason a children's institute is doing Alzheimer's work. Researchers at Texas Children's study how the brain assembles and operates in early life, and that vantage point offers clues to how the same systems fail decades later - which is where openings for prevention and treatment tend to appear.
This is foundational work rather than a treatment in hand. The team frames the effort as the first critical step toward new therapies, meaning any compounds that emerge would still face the long path of preclinical testing and clinical trials before reaching patients.